Skip to main content
. 2022 Dec 8;131:106316. doi: 10.1016/j.bioorg.2022.106316

Fig. 5.

Fig. 5

(A) Inhibitions of BA-1 against SARS-CoV-2 PsV and its mutants infections in 293 T-ACE2 cells, including N764A/R765A/Q957A/K964A. (B) Antiviral efficacy of BA-1 against SARS-CoV-2 PsV mutants caused by site-directed mutation, including N764A/R765A/Q957A/K964A.